Switch theme
Sign up to access all valuation multiples
Zhejiang Wolwo Bio-Pharmaceutical Co Ltd is a Chinese bio-pharmaceutical company. It is engaged in the research development, production and sales of allergic diseases diagnosis and treatment products. The product portfolio of the company covers dust mites drops, dust mites skin prick diagnosis kit, silk, and others.
2002
n/a
LTM Revenue n/a
LTM EBITDA n/a
$1.3B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Zhejiang Wolwo Bio-Pharma has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Zhejiang Wolwo Bio-Pharma achieved revenue of $117M and an EBITDA of $53.1M.
Zhejiang Wolwo Bio-Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Zhejiang Wolwo Bio-Pharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $117M | n/a | XXX | XXX | XXX |
| Gross Profit | $107M | $118M | XXX | XXX | XXX |
| Gross Margin | 91% | NaN% | XXX | XXX | XXX |
| EBITDA | $53.1M | n/a | XXX | XXX | XXX |
| EBITDA Margin | 45% | NaN% | XXX | XXX | XXX |
| Net Profit | $46.6M | $48.1M | XXX | XXX | XXX |
| Net Margin | 40% | NaN% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Zhejiang Wolwo Bio-Pharma's stock price is CNY 21 (or $3).
Zhejiang Wolwo Bio-Pharma has current market cap of CNY 10.8B (or $1.5B), and EV of CNY 9.6B (or $1.3B).
See Zhejiang Wolwo Bio-Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.3B | $1.5B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Zhejiang Wolwo Bio-Pharma has market cap of $1.5B and EV of $1.3B.
Zhejiang Wolwo Bio-Pharma's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Zhejiang Wolwo Bio-Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Zhejiang Wolwo Bio-Pharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.3B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpZhejiang Wolwo Bio-Pharma's NTM/LTM revenue growth is n/a
Zhejiang Wolwo Bio-Pharma's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Zhejiang Wolwo Bio-Pharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Zhejiang Wolwo Bio-Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Zhejiang Wolwo Bio-Pharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 18% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 13% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 58% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Zhejiang Wolwo Bio-Pharma acquired XXX companies to date.
Last acquisition by Zhejiang Wolwo Bio-Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Zhejiang Wolwo Bio-Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Zhejiang Wolwo Bio-Pharma founded? | Zhejiang Wolwo Bio-Pharma was founded in 2002. |
| Where is Zhejiang Wolwo Bio-Pharma headquartered? | Zhejiang Wolwo Bio-Pharma is headquartered in China. |
| Is Zhejiang Wolwo Bio-Pharma publicy listed? | Yes, Zhejiang Wolwo Bio-Pharma is a public company listed on SHE. |
| What is the stock symbol of Zhejiang Wolwo Bio-Pharma? | Zhejiang Wolwo Bio-Pharma trades under 300357 ticker. |
| When did Zhejiang Wolwo Bio-Pharma go public? | Zhejiang Wolwo Bio-Pharma went public in 2014. |
| Who are competitors of Zhejiang Wolwo Bio-Pharma? | Similar companies to Zhejiang Wolwo Bio-Pharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Zhejiang Wolwo Bio-Pharma? | Zhejiang Wolwo Bio-Pharma's current market cap is $1.5B |
| Is Zhejiang Wolwo Bio-Pharma profitable? | Yes, Zhejiang Wolwo Bio-Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
